Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Dosing also diverged from the approved label. Regorafenib's standard dose (RSD) is an average daily dose of 160 mg for 21 days of a 28-day cycle, yet more than a quarter of patients (26.5%) were ...
However, the risk of these rare cancers is not enough to dissuade prescribing CAR T-cell therapy for CLL, explains Kerry Rogers, MD, The James.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results